|MACK -- USA Stock|| |
USD 5.16 0.11 2.18%
Dr. John Mendelsohn, M.D. is an Independent Director of the Company. He has served as a member of our board of directors since June 2012. Dr. Mendelsohn has served as the CoDirector of the Khalifa Institute for Personalized Cancer Therapy at The University of Texas MD Anderson Cancer Center since September 2011. Dr. Mendelsohn also served as President of the MD Anderson Cancer Center from 1996 to August 2011. Prior to joining the MD Anderson Cancer Center, Dr. Mendelsohn was founding director of the cancer center at the University of California San Diego and served as Chairman of Medicine at Memorial SloanKettering Cancer Center from 1985 to 1996. Dr. Mendelsohn also currently serves as the L.E. and Virginia Simmons Senior Fellow in Health and Technology Policy at the James A. Baker, III Institute for Public Policy. Dr. Mendelsohn is recognized for his research on the binding of growth factors to cell surface receptors and how they regulate cell functions, which led to the discovery, development and eventual commercialization of the cancer therapy cetuximab
Age: 78 Director Since 2012
Mendelsohn holds an M.D. from Harvard Medical School and a B.S. from Harvard College.